CERo Therapeutics Holdings, Inc. (CERO)

OTCMKTS · Delayed Price · Currency is USD
0.0350
-0.0050 (-12.50%)
At close: Feb 27, 2026
-99.89%
Market Cap 1.00M
Revenue (ttm) n/a
Net Income (ttm) -49.19M
Shares Out 28.66M
EPS (ttm) -98.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,848,295
Average Volume 741,884
Open 0.0380
Previous Close 0.0400
Day's Range 0.0350 - 0.0425
52-Week Range 0.0350 - 33.4000
Beta 0.30
RSI 28.64
Earnings Date Mar 23, 2026

About CERO

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol CERO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.